During the past decade, Lancaster Urology conducted 20 clinical trials. In the 10-year time frame, 20 clinical trials started and 12 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Lancaster Urology" #1 sponsor was "Janssen Research & Development, LLC" with 6 trials, followed by "Pfizer" with 5 trials sponsored, "GTx" with 4 trials sponsored, "Dendreon" with 3 trials sponsored and "Abbott" with 3 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 32 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Lancaster Urology" #1 collaborator was "Astellas Pharma Inc" with 5 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 3 trials as a collaborator, "Lancaster Urology" with 2 trials as a collaborator, "Allergan" with 1 trials as a collaborator and "Barbara Ann Karmanos Cancer Institute" with 1 trials as a collaborator. Other collaborators include 49 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Lancaster Urology" are "Prostate Cancer" (18 trials), "Prostatic Neoplasms" (4 trials), "Metastatic Prostate Cancer" (3 trials), "Prostate Cancer Metastatic" (3 trials) and "Bladder Cancer" (2 trials). Many other conditions were trialed in "Lancaster Urology" in a lesser frequency.

Most popular intervention types in "Lancaster Urology" are "Drug" (35 trials), "Biological" (9 trials), "Other" (6 trials), "Procedure" (2 trials) and "Behavioral" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Enzalutamide" (6 trials), "Prednisone" (3 trials), "Apalutamide" (2 trials) and "Apaziquone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Lancaster Urology" are 40 trials for "Male" genders and 8 trials for "All" genders.

Currently, there are NaN active trials in "Lancaster Urology". undefined are not yet recruiting, 6 are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 23 completed trials in Lancaster Urology, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Lancaster Urology, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 23 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".